diffuse large B cell lymphoma (DLBCL)

March 12, 2020March 12, 2020

CLR 131 Shows Anti-tumor Activity, Safety in Difficult-to-treat B-cell Lymphoma Trial

News

Cellectar Biosciences has announced positive trial results demonstrating that its investigational therapy CLR 131 significantly reduced tumor activity, with tolerable safety, in B-cell lymphoma patients who received prior treatments. A “notable” ... Read more

February 18, 2020February 18, 2020

CAR T-cell Therapy Liso-cel Under FDA Priority Review for Relapsed or Refractory Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has agreed to review Bristol-Myers Squibb’s request to approve the investigational CAR T-cell therapy lisocabtagene maraleucel (liso-cel) for treating adults with relapsed or ... Read more

January 23, 2020

Polivy Triple Combo Approved in Europe for Select Patients with Advanced DLBCL

News

The European Commission has conditionally approved Roche’s Polivy (polatuzumab vedotin), in combination with rituximab and bendamustine, to treat people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for a hematopoietic (blood) stem cell transplant (HSCT). ... Read more

January 14, 2020January 14, 2020

MorphoSys Requests FDA Approval of Tafasitamab for Relapsed or Refractory DLBCL

News

MorphoSys is asking the U.S. Food and Drug Administration (FDA) to approve its CD19 antibody tafasitamab, in combination with Revlimid (lenalidomide), to treat patients with relapsed or refractory diffuse large B-cell lymphoma ... Read more

November 14, 2019December 20, 2019

FDA Grants Fast Track Status to Triumvira’s T-cell Therapy TAC01-CD19 for DLBCL

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Triumvira Immunulogics‘ investigational T-cell therapy TAC01-CD19 for the treatment of relapsed or refractory diffuse large B-cell lymphoma ... Read more

November 7, 2019November 7, 2019

First Patient Enrolled in Trial Testing Defitelio to Prevent Neurotoxicity in DLBCL Patients Receiving CAR T-cell Therapy

News

Jazz Pharmaceuticals has enrolled the first participant in a Phase 2 trial assessing the efficacy of Defitelio (defibrotide) to prevent nerve cell toxicity in people with relapsed or refractory diffuse ... Read more

October 15, 2019

Rituxan Biosimilar IBI301 Shows Similar Safety, Efficacy to Original in B-cell Lymphomas, Trials Show

News

IBI301, a biosimilar to Rituxan (rituximab), has a similar response rate to the original compound in people with B-cell lymphomas, and behaves similarly inside the body, preliminary results of two trials ... Read more

October 4, 2019October 25, 2019

CLR 131 Works to Halt Cancer Growth and Lower Tumor Volume in DLBCL, Early Phase 2 Data Show

News

Cellectar Biosciences’ investigational radiotherapeutic compound, CLR 131, effectively halted cancer progression and reduced tumor size in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), interim data of a Phase 2 trial ... Read more

August 6, 2019

Phase 1 Trial of Betalutin, a Radioimmunotherapy, in Advanced DLBCL Now Fully Enrolled

News

The Phase 1 trial evaluating Betalutin — an investigational tumor-targeting antibody labeled with a type of radiation — in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is now fully ... Read more

August 2, 2019August 2, 2019

First Patient Dosed in Trial Testing Abexinostat-Imbruvica Combo for Advanced Lymphomas

News

Xynomic Pharma has initiated patient dosing in a Phase 1/2 trial testing its investigational therapy abexinostat, in combination with Imbruvica (ibrutinib), as a treatment for people with mantle cell lymphoma (MCL) and ... Read more